Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10548904 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(6 years from now) | |
US10537584 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(6 years from now) | |
US8580293 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 29, 2023 |
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM;VAGINAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic